Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

3(42.9%)

Phase 1

2(28.6%)

Phase 3

2(28.6%)

7Total

Phase 2(3)

Phase 1(2)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04686773Phase 2Completed

Open-label, Non-randomized, Non-comparative, Phase II Study of Safety and Immunogenicity of Combination of AZD1222 and rAd26-S for COVID-19 Prevention

Role: collaborator

NCT04684446Phase 1Completed

Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19

Role: collaborator

NCT04988048Phase 2Unknown

Collaborative Study to Evaluate Heterologous Vaccination Against Covid-19 in Argentina

Role: collaborator

NCT04640233Phase 2Unknown

Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Сov-2) Infection

Role: collaborator

NCT04741061Phase 3Unknown

Study to Evaluate Efficacy, Immunogenicity and Safety of the Sputnik-Light

Role: collaborator

NCT04713488Phase 1Unknown

An Open Study on the Safety, Tolerability, and Immunogenicity of "Sputnik Light" Vaccine

Role: collaborator

NCT04564716Phase 3Unknown

Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 in Belarus

Role: collaborator

All 7 trials loaded